Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. (Q39002230)

8 September 2017

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. (English)

1 reference

8 September 2017

1 reference

1 reference

1 reference

2

Daniel Podzamczer

0 references

author name string

Arkaitz Imaz

series ordinal

1

1 reference

PubMed ID

28117606

8 September 2017

Daniel Podzamczer

series ordinal

2

1 reference

8 September 2017

24 January 2017

1 reference

Expert Review of Anti-infective Therapy

8 September 2017

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

8 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

The end of AIDS: HIV infection as a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Association of tenofovir exposure with kidney disease risk in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Renal function with use of a tenofovir-containing initial antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Antiretroviral Therapy for the Prevention of HIV-1 Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Abacavir and cardiovascular disease: A critical look at the data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Emtricitabine: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Elvitegravir: a review of its use in adults with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind,

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2017.1286736

10.1080/14787210.2017.1286736

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

28117606